Is VANI or VIR more undervalued in 2026?

CirclFi compares Vivani Medical, Inc. (VANI) and Vir Biotechnology, Inc. (VIR) using 13 institutional-grade valuation models. VANI has a Quality of Company score of 4.4/10 while VIR scores 7.0/10.

Which is a better buy — VANI or VIR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VANI and VIR valuations compare?

VANI at $1.29 and VIR at $9.55 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VANI vs VIR Valuation Comparison 2026 — Intrinsic Value Analysis

VANI

Biotechnology

Vivani Medical, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$1.29

Last close

Models

7/13

Active

VIR

Biotechnology

Vir Biotechnology, Inc.

Quality

7.0

out of 10

Value Trap

SAFE

Price

$9.55

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	VANI Fair Value	VANI Upside	VIR Fair Value	VIR Upside
Bayesian DCF	Intrinsic	$0.39	-70.2%	$2.52	-73.6%
Earnings Power Value	Intrinsic	—	—	$5.74	-42.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.43	-66.6%	$3.78	-60.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VANI vs VIR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VANI vs VIR — Which Stock Is More Undervalued?

VIR scores higher with a 7.0/10 quality rating vs VANI's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vivani Medical, Inc. (VANI) and Vir Biotechnology, Inc. (VIR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VANI currently trades at $1.29 with a QOC of 4.4/10, while VIR trades at $9.55 with a QOC of 7.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).